China brain computer interface outfit accelerates to human trials in quest to outpace Neuralink - mix of government backing and investor enthusiasm speeds time to market for NeuroXess

• China’s NeuroXess accelerates to human trials, aiming to outpace Neuralink. • Founded in 2021, the Shanghai-based firm reports successful invasive BCI trials. • A paralyzed patient used a BCI‑controlled cursor for computing tasks within five days post‑implant. • China’s state‑backed BCI blitz includes 10 invasive trial programs and a 2030 world‑class goal. • Government policy streamlines planning, regulatory approval, and financing to accelerate BCI progress. • Investor enthusiasm fuels rapid development, positioning NeuroXess as a potential 2030 BCI leader.

Article Summaries:

• China’s brain‑computer interface (BCI) sector has become a national priority, with a 2024 policy roadmap streamlining funding, regulation and planning. Shanghai‑based NeuroXess, founded in 2021, has leveraged this environment and investor enthusiasm to enter human trials within five years. The company’s invasive, non‑penetrating BCI has enabled a paralyzed patient to control a computer cursor just five days post‑implant, achieving 5.2 bps data rates-half of Neuralink’s reported 10 bps. NeuroXess’s approach avoids tissue‑penetrating electrodes, potentially reducing long‑term scarring. The rapid progress positions NeuroXess as a leading contender to meet China’s goal of producing two to three world‑class BCI firms by 2030.

Sources:

• https://www.tomshardware.com/peripherals/wearable-tech/china-brain-computer-interface-outfit-accelerates-to-human-trials-in-quest-to-outpace-neuralink-mix-of-government-backing-and-investor-enthusiasm-speeds-time-to-market-for-neuroxess